TN2011000456A1 - Treatment of pancreatic cancer - Google Patents

Treatment of pancreatic cancer

Info

Publication number
TN2011000456A1
TN2011000456A1 TN2011000456A TN2011000456A TN2011000456A1 TN 2011000456 A1 TN2011000456 A1 TN 2011000456A1 TN 2011000456 A TN2011000456 A TN 2011000456A TN 2011000456 A TN2011000456 A TN 2011000456A TN 2011000456 A1 TN2011000456 A1 TN 2011000456A1
Authority
TN
Tunisia
Prior art keywords
iodophenylamino
fluoro
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Application number
TN2011000456A
Other languages
English (en)
Inventor
Mark S Chapman
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of TN2011000456A1 publication Critical patent/TN2011000456A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TN2011000456A 2009-03-11 2011-09-09 Treatment of pancreatic cancer TN2011000456A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15939709P 2009-03-11 2009-03-11
PCT/US2010/027021 WO2010105082A1 (fr) 2009-03-11 2010-03-11 Traitement d'un cancer du pancréas

Publications (1)

Publication Number Publication Date
TN2011000456A1 true TN2011000456A1 (en) 2013-03-27

Family

ID=42129806

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000456A TN2011000456A1 (en) 2009-03-11 2011-09-09 Treatment of pancreatic cancer

Country Status (20)

Country Link
US (1) US20120053211A1 (fr)
EP (1) EP2405907A1 (fr)
JP (1) JP2012520319A (fr)
KR (1) KR20110128916A (fr)
CN (1) CN102438609A (fr)
AU (1) AU2010224108A1 (fr)
BR (1) BRPI1009435A2 (fr)
CA (1) CA2754891A1 (fr)
CL (1) CL2011002234A1 (fr)
CR (1) CR20110478A (fr)
EA (1) EA201101305A1 (fr)
IL (1) IL215037A0 (fr)
MA (1) MA33109B1 (fr)
MX (1) MX2011009494A (fr)
SG (1) SG174271A1 (fr)
SV (1) SV2011004017A (fr)
TN (1) TN2011000456A1 (fr)
TW (1) TW201100081A (fr)
UY (1) UY32486A (fr)
WO (1) WO2010105082A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2496575B1 (fr) 2009-11-04 2014-04-30 Novartis AG Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
WO2014071183A1 (fr) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Méthode de réduction des effets secondaires chez un patient souffrant de cancer traité par un inhibiteur de la mek
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101980809B1 (ko) * 2017-09-29 2019-05-21 대한민국 귀리껍질 추출물을 포함하는 췌장암의 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9022A (en) * 1852-06-15 Organ
US8005A (en) * 1851-04-01 He ne y bo o t
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2649122C (fr) * 2006-04-18 2015-06-30 Ardea Biosciences, Inc. Sulfonamides pyridone et sulfamides pyridone en tant qu'inhibiteurs de mek
MX2010001244A (es) * 2007-07-30 2010-08-31 Ardea Biosciences Inc Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek asi como composiciones, metodos de uso y de preparacion de los mismos.
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof

Also Published As

Publication number Publication date
AU2010224108A1 (en) 2011-09-22
EA201101305A1 (ru) 2012-04-30
MA33109B1 (fr) 2012-03-01
CL2011002234A1 (es) 2012-01-27
IL215037A0 (en) 2011-11-30
BRPI1009435A2 (pt) 2016-03-01
TW201100081A (en) 2011-01-01
US20120053211A1 (en) 2012-03-01
SV2011004017A (es) 2012-01-06
UY32486A (es) 2010-10-29
JP2012520319A (ja) 2012-09-06
WO2010105082A1 (fr) 2010-09-16
CR20110478A (es) 2011-10-24
MX2011009494A (es) 2011-10-11
CN102438609A (zh) 2012-05-02
EP2405907A1 (fr) 2012-01-18
SG174271A1 (en) 2011-10-28
KR20110128916A (ko) 2011-11-30
CA2754891A1 (fr) 2010-09-16

Similar Documents

Publication Publication Date Title
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
CY1121729T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
WO2013188792A3 (fr) Stéroïdes neuroactifs, compositions, et leurs utilisations
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX2014003080A (es) Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c.
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
JP2017530983A5 (fr)
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
JOP20190050A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
MX2009011900A (es) Curacion de herida diabetica.
MX2009005798A (es) Recuperacion de apoplejia.
TN2011000456A1 (en) Treatment of pancreatic cancer
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
MX2019008181A (es) Inhibidores selectivos hdac6, metodos de preparacion y aplicacion de los mismos.
IN2014KN01113A (fr)